Oppenheimer reiterated an Outperform rating on Thoratec Corp. THOR and a $42 price target.
Oppenheimer commented, “THOR delivered another solid quarter in 2Q and raised '12 guidance. Sales were ahead of our thinking and a touch below consensus at $118.6M (Opco/Street at $115.3M/$120.4M). EPS was ahead of us at $0.45 (Opco/Street at $0.43/$0.45). The message was consistent with what we heard in 1Q: market growth in LVADs remains robust. THOR has used its strong performance to reinvest in market initiatives for future growth.”
Thoratec closed at $34 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in